TPWA
ADCT icon

Twin Peaks Wealth Advisors’s ADC Therapeutics ADCT Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$8 – 257
2026
Q1 		$8 Buy
+2
New +$8 ﹤0.01% 2367

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Twin Peaks Wealth Advisors's ADCT Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 2 shares — an estimated $8 sold.

Twin Peaks Wealth Advisors first reported a position in ADCT in Q1 2026 and held it in 1 quarter. The position peaked at $8 in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 2 ADC Therapeutics shares in Q2 2026, an estimated $8.
  • Twin Peaks Wealth Advisors first reported a position in ADC Therapeutics in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's ADC Therapeutics position peaked at $8 in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.